Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986525 Monotherapy and Combination Therapy in Relapsed/Refractory Small Cell Lung Cancer
NCT07325136Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Primary completion
- Apr 2029
- Countries
- 6
01
Overview
A Phase 2 trial of BMS-986525 in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Feb 2026; status: recruiting.
02
Drugs
BMS-986525
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07325136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325136.